Vaxzevria, the successful coronavirus vaccine developed by AstraZeneca in partnership with the University of Oxford, is being withdrawn from the market due to decreased demand. Despite its widespread use and over 3 billion doses administered since January 4, 2021, the vaccine has not generated any revenue for AstraZeneca since April 2023.
The decline in demand led AstraZeneca to initiate the withdrawal of its marketing authorizations within Europe. The European Medicines Agency (EMA) also announced that the vaccine was no longer authorized for marketing or sale in EU countries. AstraZeneca will work with regulators in other countries to align on the next steps, including withdrawing marketing authorizations where there is no future commercial demand expected.
AstraZeneca expressed pride in Vaxzevria’s role in combating the global pandemic, stating that their efforts have been recognized by governments worldwide as a critical component in ending it. This is a developing story and will be updated as more information becomes available.